CTLA4 and colorectal carcinoma: As part of the ongoing CheckMate142 trial, the combination of CTLA-4 and PD-1 inhibitors in previously treated dMMR MSI-H CRC demonstrated a favourable progression free and overall survival rate at 12 months follow up (71, 85% respectively) [18].